CagriSema降低超重或肥胖成年人预测的动脉粥样硬化性心血管疾病风险：REDEFINE 1试验.pdf

1、Verma S.et al.Presented at the 33rd European Congress on Obesity(ECO),May 1215,2026;Istanbul,Trkiye.CagriSema reduces predicted atherosclerotic cardiovascular disease risk in adults with overweight or obesity:The REDEFINE 1 trialSubodh Verma1,Morten Bttcher2,Paul Brown3,Dror Dicker4,Domenica Rubino5

2、,Paolo Sbraccia6,Arya M.Sharma7,Lrke Smedegaard3,Rasmus Srrig3,W.Timothy Garvey81Division of Cardiac Surgery,Li Ka Shing Knowledge Institute of St.Michaels Hospital,University of Toronto,Toronto,ON,Canada;2University Clinic for Cardiovascular Research,Institute of Clinical Medicine,Aarhus University

3、,and Department of Cardiology,Gdstrup Hospital,Herning,Denmark;3Novo Nordisk A/S,Sborg,Denmark;4Department of Internal Medicine D and Obesity Clinic,Hasharon Hospital,Rabin Medical Center,Petah Tikva,Israel;5Washington Center for Weight Management&Research,Arlington,VA,USA;6Department of Systems Med

4、icine,University of Rome Tor Vergata,Rome,Italy;7Department of Medicine,University of Alberta,Edmonton,AB,Canada;8Department of Nutrition Sciences,University of Alabama at Birmingham,Birmingham,AL,USA.This trial was sponsored by Novo Nordisk A/S and is registered with ClinicalTrials.gov(NCT05567796)

5、.Medical writing support was provided by James Parkinson,PhD,CMPP,of Apollo,OPEN Health Communications,and funded by Novo Nordisk A/S,in accordance with Good Publication Practice(GPP)guidelines(ismpp.org/gpp-2022).Previously presented at the 43rdAnnual Meeting of The Obesity Society)held at ObesityW

6、eek,November 47,2025,Atlanta,GA,USAScan QR code or visit the website below for:Science Hub linkshttps:/ S.et al.Presented at the 33rd European Congress on Obesity(ECO),May 1215,2026;Istanbul,Trkiye.2Presenter disclosureArya M.Sharma reports the following:Receiving honoraria for consulting and/or spe